Humana (HUM) Projected to Post Earnings on Wednesday

Humana (NYSE:HUM) is expected to be releasing its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect Humana to post earnings of $2.95 per share and revenue of $31.9907 billion for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 6:00 AM ET.

Humana Stock Down 2.7%

NYSE:HUM opened at $278.02 on Monday. Humana has a 1-year low of $206.87 and a 1-year high of $315.35. The company has a 50-day moving average of $281.34 and a 200 day moving average of $258.62. The firm has a market cap of $33.44 billion, a PE ratio of 21.34, a price-to-earnings-growth ratio of 1.71 and a beta of 0.42. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.95 and a quick ratio of 1.95.

Humana Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Friday, December 26th will be given a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a dividend yield of 1.3%. The ex-dividend date of this dividend is Friday, December 26th. Humana’s dividend payout ratio is presently 27.17%.

Hedge Funds Weigh In On Humana

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Man Group plc raised its position in shares of Humana by 179.5% in the 2nd quarter. Man Group plc now owns 580,943 shares of the insurance provider’s stock valued at $142,029,000 after purchasing an additional 373,071 shares during the last quarter. 8 Knots Management LLC raised its position in shares of Humana by 671.0% in the 2nd quarter. 8 Knots Management LLC now owns 441,623 shares of the insurance provider’s stock valued at $107,968,000 after purchasing an additional 384,345 shares during the last quarter. Canada Pension Plan Investment Board increased its holdings in Humana by 63.3% in the 2nd quarter. Canada Pension Plan Investment Board now owns 436,047 shares of the insurance provider’s stock worth $106,605,000 after buying an additional 169,068 shares during the period. Holocene Advisors LP acquired a new position in Humana in the 2nd quarter worth approximately $64,595,000. Finally, Teewinot Capital Advisers L.L.C. acquired a new position in Humana in the 2nd quarter worth approximately $52,058,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have commented on the stock. Bank of America increased their price target on shares of Humana from $280.00 to $300.00 and gave the company a “neutral” rating in a research report on Friday, October 10th. The Goldman Sachs Group assumed coverage on shares of Humana in a research report on Tuesday, October 14th. They set a “sell” rating and a $235.00 price target for the company. Truist Financial set a $300.00 price target on shares of Humana in a research report on Tuesday, October 14th. Royal Bank Of Canada increased their price target on shares of Humana from $283.00 to $322.00 and gave the company an “outperform” rating in a research report on Thursday, August 21st. Finally, Wolfe Research increased their price target on shares of Humana from $283.00 to $313.00 and gave the company an “outperform” rating in a research report on Monday, October 6th. Eight investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Humana has a consensus rating of “Hold” and a consensus target price of $297.58.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.